At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 334 enrolled
Drug / intervention
ESBA105 ophthalmic solution +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of ESBA105 in the Persistent Relief of Ocular Discomfort in Patients With Severe Dry Eye
In Brief
A Phase 2 clinical trial evaluating ESBA105 ophthalmic solution and ESBA105 vehicle for Eyes Dry Chronic. Completed, enrolled 334 participants across 1 site.
Detailed Summary
The purpose of this study was to evaluate the efficacy of ESBA105 over vehicle in reducing the ocular symptoms of dry eye disease, as measured by a mean global Visual Analog Scale (VAS) discomfort score.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEyes Dry Chronic
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2011
Enrollment StartJun 2011
Primary CompletionFeb 2012
TodayJul 2026
First PostedApr 19, 2011
Enrollment StartJun 1, 2011
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.2 years ago
Interventions
ESBA105 ophthalmic solutionbiological
ESBA105 vehicleother
Inactive ingredients used as Run-In and placebo comparator